Alkermes (ALKS) Expected to Release Quarterly Earnings on Tuesday

Alkermes (NASDAQ:ALKS) is projected to issue its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect Alkermes to post earnings of ($0.0815) per share and revenue of $463.48 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 8:00 AM ET.

Alkermes Stock Performance

Shares of ALKS opened at $45.34 on Monday. Alkermes has a twelve month low of $27.00 and a twelve month high of $55.67. The company has a current ratio of 2.30, a quick ratio of 1.85 and a debt-to-equity ratio of 0.82. The company has a market cap of $7.61 billion, a P/E ratio of 119.32 and a beta of 0.32. The company’s fifty day simple moving average is $44.06 and its 200-day simple moving average is $40.44.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on ALKS shares. Truist Financial assumed coverage on Alkermes in a research report on Friday, October 16th. They set a “buy” rating and a $55.00 price objective for the company. HC Wainwright reissued a “neutral” rating on shares of Alkermes in a research note on Monday, September 21st. Royal Bank Of Canada reissued an “outperform” rating and issued a $56.00 price target on shares of Alkermes in a research report on Tuesday, September 22nd. Stifel Nicolaus restated a “buy” rating and set a $63.00 target price (up from $45.00) on shares of Alkermes in a research report on Monday, July 20th. Finally, JPMorgan Chase & Co. increased their target price on shares of Alkermes from $60.00 to $61.00 and gave the stock a “neutral” rating in a report on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $54.38.

Insider Transactions at Alkermes

In other Alkermes news, EVP David Gaffin sold 2,034 shares of Alkermes stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $41.03, for a total value of $83,455.02. Following the sale, the executive vice president directly owned 221,388 shares in the company, valued at approximately $9,083,549.64. The trade was a 0.91% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Craig C. Hopkinson sold 9,000 shares of Alkermes stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $46.99, for a total value of $422,910.00. Following the completion of the transaction, the executive vice president owned 65,389 shares in the company, valued at $3,072,629.11. This trade represents a 12.10% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 20,644 shares of company stock worth $976,984 in the last quarter. Company insiders own 4.59% of the company’s stock.

Alkermes Company Profile

Alkermes plc (NASDAQ:ALKS) is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system diseases. Its research and development activities address conditions including schizophrenia, bipolar disorder, addiction, depression and other neuropsychiatric disorders.

The company’s marketed products include Vivitrol, an extended-release injectable form of naltrexone used to treat alcohol dependence and prevent relapse to opioid dependence; Aristada and Aristada Initio, long-acting injectable formulations of aripiprazole lauroxil for the treatment of schizophrenia; and Lybalvi, a combination of olanzapine and samidorphan approved for schizophrenia and bipolar I disorder in adults.

Founded in 1987, Alkermes is incorporated in Ireland and maintains its corporate headquarters in Waltham, Massachusetts.